Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | GUSB | P08236 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515652 | 0.86 | RAB9A (0.47) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL29398836 | 0.81 | KDM4E (0.57) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL28051087 | 0.77 | GUSB (0.61) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL13789347 | 0.76 | SMN1; SMN2 (0.51) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL13789326 | 0.72 | SMN1; SMN2 (0.50) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL13789304 | 0.72 | SMN1; SMN2 (0.56) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL29397961 | 0.72 | SPR (0.69) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL22287887 | 0.72 | SPR (0.69) | SPRSMN1; SMN2RAB9AMAPTPDE5A | |
| SCHEMBL5266417 | 0.71 | SPR (0.54) | SPRSMN1; SMN2RAB9AMAPTCDK9 | |
| SCHEMBL18702370 | 0.71 | SPR (1.00) | SPRSMN1; SMN2RAB9AMAPTPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557112-B2 | Aromatic-ring-fused pyrimidine derivative | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20070249587-A1 | Aromatic-Ring-Fused Pyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1806347-A1 | AROMATIC-RING-FUSED PYRIMIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249587-A1 | Aromatic-Ring-Fused Pyrimidine Derivative | GPR119, NOD1, IRS1 | SPR 3329/4885SMN1; SMN2 2701/4885RAB9A 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.